Yearly Archives: "2018"

Call for test sites: using patient-reported outcomes to drive multiple sclerosis care
Researchers at Northwestern University are seeking volunteers to participate in the pilot testing of a new quality measure for [...]
Researchers have a new theory about what may cause multiple sclerosis
When the following headline in the Australian newspaper the Herald Sun caught my eye recently, I was cautiously intrigued: “Doctors [...]
FDA accepts file for Cladribine tablets as potential treatment for relapsing forms of multiple sclerosis
PDF ROCKLAND, Mass., July 30, 2018 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and [...]
Temperament can play a big role in quality of life with multiple sclerosis
Researchers say if a person with multiple sclerosis is irritable or anxious, it can make overcoming the obstacles of their disease much [...]
Genentech announces new Ocrevus (Ocrelizumab) data for PPMS
Dear Advocates, We are pleased to announce that new OCREVUS® (ocrelizumab) data will be presented at the 4th Congress of the European [...]
AAN publishes guideline on disease-modifying therapies for multiple sclerosis
The AAN published a new guideline, Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis, in Neurology® [...]
TREAT-MS
Dr. Scott Newsome and Dr. Ellen Mowry are pleased to announce the launch of their TREAT-MS trial at Hopkins. They will be activating and [...]
New Ocrevus (Ocrelizumab) data demonstrate reductions In activity & progression In RMS
We are pleased to announce that new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual [...]
Imagerywork
Dr. Miriam Franco, PSY.D, MSCS, has developed a new APP that includes a separate page for Guided Imagery for MS, Improving Mood, Relieving [...]
Phase III data in the lancet show Novartis outcomes in secondary progressive multiple sclerosis
EAST HANOVER, N.J., March 22, 2018 – Novartis today announced that the full results from the Phase III EXPAND study of oral, [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM